Halle An Der Saale, Germany
Halle An Der Saale, Germany
SEARCH FILTERS
Time filter
Source Type

A method for predicting, diagnosing and prognosticating a neurodegenerative disease, such as Alzheimers disease (AD), Mild Cognitive Impairment (MCI) and neurodegeneration in Downs syndrome (NDS) using glutaminyl cyclase (QC) as a diagnostic/prognostic indicator. The use of antibodies binding to QC and kits for performing said diagnostic method are also provided.


Patent
Probiodrug | Date: 2015-04-29

The present invention relates to compounds of formula (I), combinations and uses thereof for disease therapy,A represents^(1), R^(2), R^(3), R^(4), R^(5), R^(6) and Z are as defined throughout the description and the claims.


Patent
Probiodrug | Date: 2016-07-27

The present invention pertains to novel diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimers disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.


A transgenic non-human animal for overexpressing isoQC, comprising cells containing a DNA transgene encoding human isoQC, characterized in that said human isoQC comprises the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 75% sequence identity to the amino acid sequence of SEQ ID NO: 1 or a fragment or derivative of the amino acid sequence of SEQ ID NO: 1. Additionally disclosed is a method of screening for biologically active agents that inhibit or promote isoQC.


Patent
Probiodrug | Date: 2015-09-03

Novel diagnostic assays for the diagnosis of amyloidosis, in particular Alzheimers disease, and related aspects. In particular, monoclonal antibodies and an antibody assay are provided.


Patent
Probiodrug | Date: 2014-03-14

The invention relates to a compound of formula (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof, wherein R^(1), R^(2), R^(3), R^(4 )and R^(5 )are as defined herein, as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.


Monoclonal antibodies which bind specifically to the proinflammatory cytokine pyroglutamate MCP-1 (MCP-1 N1pE).


Patent
Probiodrug | Date: 2015-09-23

The invention relates to novel pyrrolidine derivatives of formula (I): wherein R^(1), R^(2 )and R^(3 )are as defined herein, as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.


A method for predicting, diagnosing and prognosticating a neurodegenerative disease, such as Alzheimers disease (AD), Mild Cognitive Impairment (MCI) and neurodegeneration in Downs syndrome (NDS) using glutaminyl cyclase (QC) as a diagnostic/prognostic indicator. The use of antibodies binding to QC and kits for performing said diagnostic method are also provided.


Radiolabeled glutaminylcyclase (QC) inhibitors as imaging agents, in particular, but not exclusively, as medical imaging agents for the detection of neurological disorders; and pharmaceutical compositions, methods and kits for detecting neurological disorders, using the radiolabeled inhibitors.

Loading Probiodrug collaborators
Loading Probiodrug collaborators